SLNO - Soleno Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.10
+0.06 (+2.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.04
Open2.00
Bid1.35 x 800
Ask2.50 x 800
Day's Range1.97 - 2.19
52 Week Range1.32 - 3.60
Volume83,371
Avg. Volume30,373
Market Cap44.969M
Beta (3Y Monthly)-0.16
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical data from a Phase II study (PC025) of diazoxide choline controlled release (DCCR) investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome (PWS) were delivered today in a poster presentation at the Obesity Society Meeting 2018, taking place this week in Nashville, TN. “While the hallmark characteristic of PWS is hyperphagia, PWS patients also experience ectopic accumulation of body fat, obesity and associated cardiometabolic complications, which is the leading cause of death of PWS patients,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.

  • GlobeNewswire2 days ago

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    REDWOOD CITY, Calif., Nov. 15, 2018 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • GlobeNewswirelast month

    Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data supporting a potential mechanism of action paired with phase II data, and clinical safety data of diazoxide choline controlled release (DCCR), supporting the Phase III study design in Prader-Willi Syndrome (PWS), were presented in oral and poster presentations on October 4, 2018, at the 2018 Foundation for Prader-Willi Research Annual Conference (FPWR), in Las Vegas. “The data presented on DCCR at this year’s FPWR continue to support the design of our ongoing Phase 3 trial,” said Anish Bhatnagar M.D., Chief Executive Officer of Soleno Therapeutics.

  • GlobeNewswire2 months ago

    Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical pharmacokinetic and glycemic impact data from studies of Soleno’s lead product candidate, diazoxide chloride controlled release (DCCR) for the treatment of Prader-Willi Syndrome (PWS), were presented as two posters during a late-breaking session on September 29, 2018, at the 57th Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Athens, Greece. “The pharmacokinetic data presented at ESPE clearly demonstrate that DCCR is suitable for once-daily dosing, which is important for patient compliance, particularly in children,” said Anish Bhatnagar M.D., chief executive officer of Soleno Therapeutics.  “In addition, DCCR’s constant intraday circulating drug levels have the potential to reduce the likelihood of adverse events that can be associated with drug level fluctuations.

  • GlobeNewswire2 months ago

    Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease

    REDWOOD CITY, Calif., Sept. 19, 2018-- Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish ...

  • GlobeNewswire2 months ago

    Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology

    REDWOOD CITY, Calif., Sept. 17, 2018-- Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases will present two poster presentations ...

  • GlobeNewswire2 months ago

    Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients

    Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a protocol amendment to its ongoing Phase III trial, DESTINY PWS, studying Diazoxide Choline Controlled-Release (DCCR) tablets in Prader-Willi syndrome (PWS). The protocol amendment reduces the age of inclusion to children as young as four years of age, from eight years of age previously.

  • GlobeNewswire2 months ago

    Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (No. 10/058,557) from the U.S. Patent and Trademark Office related to the use of pharmaceutical formulations of diazoxide and diazoxide choline to increase lean body mass and the lean body mass/fat mass ratio in patients with Prader-Willi syndrome (PWS). PWS is a rare and complex genetic neurobehavioral and metabolic disorder affecting appetite, body composition, growth, metabolism, cognitive function, and behavior.

  • What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?
    Simply Wall St.7 months ago

    What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?

    The latest earnings update Soleno Therapeutics Inc’s (NASDAQ:SLNO) released in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below isRead More...

  • Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?
    Simply Wall St.8 months ago

    Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?

    When Soleno Therapeutics Inc (NASDAQ:SLNO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...

  • Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?
    Simply Wall St.8 months ago

    Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?

    Soleno Therapeutics Inc’s (NASDAQ:SLNO): Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. With the latest financial year loss of -US$10.39MRead More...

  • ACCESSWIRE11 months ago

    Today’s Research Reports on Stocks to Watch: Soleno Therapeutics and La Jolla Pharmaceutical Company

    NEW YORK, NY / ACCESSWIRE / December 11, 2017 / Soleno Therapeutics headed higher on Friday after its wholly-owned subsidiary Capnia Inc. entered into a joint venture with OptAsia Healthcare Limited of ...

  • Is Soleno Therapeutics Inc’s (SLNO) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.11 months ago

    Is Soleno Therapeutics Inc’s (SLNO) Balance Sheet Strong Enough To Weather A Storm?

    The direct benefit for Soleno Therapeutics Inc (NASDAQ:SLNO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...

  • Should Soleno Therapeutics Inc’s (SLNO) Earnings Decline In Recent Times Worry You?
    Simply Wall St.last year

    Should Soleno Therapeutics Inc’s (SLNO) Earnings Decline In Recent Times Worry You?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...